Valuation: Chugai Pharmaceutical Co., Ltd.

Market Cap 11,267B 68.83B 60.45B 56.22B 51.59B 96.93B 6,628B 98.43B 668B 261B 3,259B 258B 253B P/E 2026 *
24.1x
P/E 2027 * 20.6x
Enterprise Value 10,299B 62.92B 55.26B 51.39B 47.16B 88.6B 6,059B 89.97B 610B 238B 2,979B 236B 231B EV / Sales 2026 *
7.42x
EV / Sales 2027 * 6.57x
Free-Float
38.12%
Yield 2026 *
1.84%
Yield 2027 * 2.12%
1 day-7.66%
1 week-7.42%
Current month-9.11%
1 month-9.59%
3 months-8.02%
6 months-20.76%
Current year-16.92%
1 week 6,795
Extreme 6795
7,509
1 month 6,795
Extreme 6795
7,939
Current year 6,795
Extreme 6795
10,700
1 year 5,942
Extreme 5942
10,700
3 years 3,990
Extreme 3990
10,700
5 years 3,191
Extreme 3191
10,700
10 years 1,003.33
Extreme 1003.3333
10,700
Manager TitleAgeSince
Chief Executive Officer 63 01/03/2021
Director of Finance/CFO 59 28/03/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 63 01/03/2020
Director/Board Member 59 28/03/2024
Director/Board Member 51 01/03/2025
Change 5-day change 1-year change 3-year change Capi.($)
-7.66%-7.42%-7.82%+67.07% 74.54B
+0.57%+4.39%+48.15%+163.13% 1,067B
+1.36%+6.38%+59.25%+52.40% 635B
+0.55%+3.03%+38.47%+75.37% 458B
+1.93%+8.47%+38.07%+32.06% 347B
+1.74%+4.60%+37.95%+41.88% 295B
+2.28%+4.12%+19.46%+20.47% 262B
+1.46%-1.07%-28.07%-39.03% 216B
+1.31%+4.32%+26.09%+60.94% 203B
+1.85%-1.36%+16.25%+71.74% 161B
Average +0.56%+1.32%+24.78%+54.60% 371.8B
Weighted average by Cap. +1.08%+1.94%+36.95%+78.29%

Financials

2026 *2027 *
Net sales 1,388B 8.48B 7.45B 6.93B 6.36B 11.95B 817B 12.13B 82.27B 32.14B 402B 31.84B 31.15B 1,538B 9.39B 8.25B 7.67B 7.04B 13.23B 905B 13.43B 91.11B 35.59B 445B 35.26B 34.5B
Net income 507B 3.1B 2.72B 2.53B 2.32B 4.36B 298B 4.43B 30.04B 11.74B 147B 11.63B 11.38B 592B 3.62B 3.18B 2.95B 2.71B 5.09B 348B 5.17B 35.09B 13.71B 171B 13.58B 13.29B
Net Debt -968B -5.91B -5.19B -4.83B -4.43B -8.33B -569B -8.46B -57.36B -22.41B -280B -22.2B -21.72B -1,164B -7.11B -6.24B -5.81B -5.33B -10.01B -685B -10.17B -68.95B -26.94B -337B -26.69B -26.11B
Logo Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Employees
5,104
Date Price Change Volume
27/07/26 ¥6,848.00 -7.66% 6,311,000
24/07/26 ¥7,416.00 +2.83% 2,827,400
23/07/26 ¥7,212.00 -1.29% 2,609,800
22/07/26 ¥7,306.00 -1.23% 2,064,700
21/07/26 ¥7,397.00 +0.98% 3,264,000
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
7,416.00JPY
Average target price
9,700.00JPY
Spread / Average Target
+30.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4519 Stock